Search Results

Jumpcode Genomics and Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., announced the companies have settled their patent dispute and have partnered to bring together their combined foundational IP in the field of targeted depletion of undesired transcripts such as ribosomal RNAs from NGS libraries using CRISPR-based technology.

Clinical Study on Track to Meet Primary Endpoints with Interim Data Demonstrating Blood-Based Assay Capable of Predicting Relapse Risk Through Analysis of Genomic Instability and Telomere Architecture

Takara Bio USA, Inc. announced that it has once again prevailed in its second patent dispute with Jumpcode Genomics, Inc.

Jumpcode Genomics today announced the results of a new study demonstrating the potential of Jumpcode Genomics depletion technology for improving future large-scale infectious disease testing and pandemic response.

Jumpcode Genomics, a genome technology platform company focused on improving the understanding of human biology, announced a partnership with 10x Genomics to integrate the Jumpcode Single Cell RNA Boost Kit with the 10x Genomics Chromium Single Cell Gene Expression platform.

New GPU-powered system reduces whole-genome processing time from hours to minutes, unlocking population-scale genetic discovery and accelerating rare disease drug development